Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E1HF
|
|||
| Former ID |
DIB004540
|
|||
| Drug Name |
FFC-14A
|
|||
| Synonyms |
KP 1019; KP-692; HInd(RuInd2CI4), University of Vienna; KP-1019 (anhydrous); Ruthenium(III) complex, Faustus Forschung
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Faustus Forschungs Cie Translational Cancer Research GmbH
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human Deoxyribonucleic acid (hDNA) | Target Info | Binder | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004610) | |||
| REF 2 | The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 2005 Aug 26;226(2):115-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.